The global HIV drugs market is anticipated to grow at a CAGR of nearly 4.2% during the forecast period (2022-2028). Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, which attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases. HIV drugs are defined as the medicines that are to be taken for the prevention of the HIV. The drugs are highly effective for preventing HIV when taken as prescribed. The major driving factors contributing to the market growth include the rising prevalence and burden of HIV, growing investment in R&D related to these drugs coupled with the rise in the availability of novel drugs that poses better efficacy. For instance, as per the US Department of Health & Human Services, in 2018, there were nearly 37.9 million people globally living with HIV/AIDS. An estimated 1.7 million individuals globally became newly infected with HIV in 2018.
These drugs are majorly available in a number of categories that broadly include integrase inhibitors, protease inhibitors, multi-class combination products, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and others. Currently, pre-exposure prophylaxis drugs are considered to be the base of HIV/AIDS treatment, since there is no solid cure or a preventive vaccine available for HIV. Thus, the presence of huge patient pool demands the pre-exposure prophylaxis drugs for the treatment of HIV, which is projected to drive the growth of the market during the forecast period.
Some key players operating in the market include GlaxoSmithKline plc, Pfizer Inc., and Gilead Sciences, Inc., among others. Some new FDA approvals for HIV drugs has been witnessed. For instance, in July 2020, the US FDA approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies owing to resistance, intolerance or safety considerations.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global HIV Drugs Market at https://orionmarketreports.com/request-sample/?id=97178&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Medication Class
- By Distribution Channel
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: GlaxoSmithKline plc, Pfizer Inc., and Gilead Sciences, Inc., among others.
A full report is available at: https://orionmarketreports.com/global-hiv-drugs-market/97178/
Global HIV Drugs Market Report by Segment
By Application
- Multi-Class Combination Drugs
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Protease Inhibitors (PIs)
- Entry Inhibitors
- HIV Integrase Stand Transfer Inhibitors
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
